Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis-Reference-Cited by-同舟云学术

Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis

Published:2021-08 Issue:4 Volume:31 Page:405-406
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Finsterer Josef

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference10 articles.

1. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab.;de Filette;J Clin Endocrinol Metab,2016

2. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.;Hakami;Endocrinol Diabetes Metab Case Rep,2019

3. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.;Irimada;J Dermatol,2019

4. Pembrolizumab-induced rhabdomyolysis with myositis in a patient with lung adenocarcinoma.;Hamada;Arch Bronconeumol (Engl Ed),2018

5. Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report.;Clark;J Immunother Cancer,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review;Clinical and Translational Oncology;2024-04-24

2. Ipilimumab/pembrolizumab;Reactions Weekly;2022-08-20

3. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis;Frontiers in Immunology;2021-12-06